<DOC>
	<DOCNO>NCT01168791</DOCNO>
	<brief_summary>This international , randomize , double-blind , placebo-controlled trial evaluate clinical efficacy palifosfamide-tris administer doxorubicin combination , compare doxorubicin administer placebo front-line patient diagnose metastatic soft tissue sarcoma ( STS ) .</brief_summary>
	<brief_title>Study Palifosfamide-tris Combination With Doxorubicin Patients With Front-line Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>To eligible , patient must meet EACH follow criterion : Age â‰¥18 year . Documented soft tissue sarcoma Metastatic disease patient receive prior treatment , treatment doxorubicin consider medically acceptable . ECOG Performance Status 0 , 1 2 Adequate bone marrow organ function base result protocol specified laboratory test Male female patient must agree use highly reliable method birth control study participation . Able provide inform consent To eligible , patient must meet NONE follow criterion : Specific sarcoma histological subtypes include GIST Ewing 's sarcoma . Systemic therapy treatment metastatic sarcoma , prior study . However , patient may receive neoadjuvant/adjuvant Gemzar Taxotere chemotherapy primary sarcoma , prior development metastatic disease Any prior anthracycline use . Known allergy study drug excipients . Any unstable clinically significant concurrent medical condition would , opinion investigator , jeopardize safety patient and/or compliance protocol , base screening test , physical examination medical history ( specifically define clinical protocol ) . Myocardial dysfunction define leave ventricular ejection fraction ( LVEF ) &lt; 50 % . Documented metastasis brain meninges . Any malignancy sarcoma within last 5 year prior screen , exception cervical carcinoma situ , basal cell carcinoma , superficial bladder tumor ( Ta , Tis , T1 ) successfully curatively treated evidence recurrent residual disease . Currently pregnant nursing . Radiotherapy curative intent within 4 week first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Front line</keyword>
</DOC>